New Drug Targets Key Genetic Driver of Cancer

Entrectinib (Rozlytrek) has been approved by the Food and Drug Administration to treat adolescent and adult patients whose solid tumor cancers are related to a specific genetic defect known as neurotrophic tyrosine receptor kinase gene fusion, and for whom there are no effective treatments.Several warnings and precautions are listed on entrectinib's labeling, including congestive heart failure, central nervous system effects, skeletal fractures, hepatotoxicity, hyperuricemia, QT interval prolongation, vision disorders, and embryo–fetal toxicity.
Source: AJN - Category: Nursing Tags: Drug Watch Source Type: research